The Benchmark indices ended on a positive note in the highly volatile session on June 20. At close, the Sensex was up 237.42 points or 0.46% at 51,597.84, and the Nifty was up 56.70 points or 0.37% at 15,350.20. About 673 shares have advanced, 2663 shares declined, and 156 shares are unchanged.
HUL, HDFC, Apollo Hospitals, Asian Paints and UltraTech Cement were among the top Nifty gainers, while losers were ONGC, Tata Steel, UPL, Hindalco Industries and Coal India.
On the sectoral front, FMCG index added 1 percent and IT index up 0.4 percent, however oil & gas, metal, capital goods, power and realty down 1-4 percent. BSE midcap index shed 1.4 percent and smallcap index fell 3 percent.
Engineers India has won three separate projects from specialized chemicals, sunrise and infrastructure sectors. It will provide consulting services and the estimated order value of these projects is approximately Rs 80 crore.
Engineers India touched 52-week low of Rs 55.95 and was quoting at Rs 56.45, down Rs 1.05, or 1.83 percent on the BSE.
Artefact Projects has bagged projects assignments with fees of Rs 30.72 crore. This can result in additional annual revenue of approximately Rs 9 crore per annum for next 3 years.
The company has participated in 65 number of bids involving fees of approximately Rs 524.42 crore, out of which some orders are further expected.
Artefact Projects was quoting at Rs 43, down Rs 5.10, or 10.60 percent.
Nazara Technologies has decided to make a further strategic investment of up to Rs 20.1 crore in material subsidiary Absolute Sports, by acquiring shares promoter Porush Jain, and up to Rs 10 crore in Brandscale Innovations by subscribing to optionally convertible debentures in one or more tranches.
Nazara Technologies touched 52-week low of Rs 1,008.05 and was quoting at Rs 1,014, down Rs 36.55, or 3.48 percent on the BSE.
The United States Food and Drug Administration (US FDA) conducted an un-announced in-person inspection of Jeevan Scientific Technology’s clinical pharmacology centre facility and a remote record review of bioanalytical facility, during May 31-June 10 and June 9-16.
Clinical pharmacology centre has received a Form 483, while there was no significant objectionable observations for bioanalytical facility.
The observations are related to procedural improvements and it has addressed most of them with required evidence(s) during closeout(s), but the outcome of the audit(s) is not restrictive in nature and do not hinder the smooth operations of both facilities.
Jeevan Scientific Technology touched a 52-week low of Rs 58.45 and was quoting at Rs 58.45, down Rs 3.05, or 4.96 percent on the BSE.
